Objective:To observe the clinical efficacy of Erxian Xiaoying Decoction combined with levothyroxine sodium in the treatment of hypothyroidism secondary to Hashimoto’s thyroiditis (Hashimoto’s hypothyroidism). Methods60 patients with Hashimoto’s hypothyroidism were randomly divided into the treatment group and control group,30 cases in each group. The control group was treated with levothyroxine sodium(Euthyrox),and the treatment group was treated with Erxian Xiaoying Decoction based on the treatment for the control group. 4 weeks were taken as a course,and both groups were treated for 3 courses. The clinical efficacy was observed,the changes on the dosage of Euthyrox,thyroid function indexes including total triiodothyronine (TT3),total thyroxine (TT4),thyroid-stimulating hormone (TSH),free triiodothyronine (FT3),free thyroxine (FT4),and related antibodies including anti-thyroid globulin antibody (TGAb) and anti-thyroid microsomal antibody (TMAb) were compared.  Results:①The total effective rates were 93.3% in the treatment group and 66.7% in the control group,and the clinical efficacy of the treatment group was better than that of the control group (P<0.05). ②Compared with treatment before,the levels of TT3,TT4,FT3 and FT4 were increased in both groups after treatment (P<0.05),while the TSH level was decreased after treatment (P<0.05). After treatment,there were statistically significant differences on the levels of all thyroid function indexes between the two groups (P<0.05). ③Compared with treatment before,the levels of TGAb and TMAb and the dosage of Euthyrox were decreased in both groups after treatment (P<0.05). After treatment,the levels of TGAb and TMAb and the dosage of Euthyrox in the treatment group were lower than those in the control group (P<0.05).  Conclusion:Erxian Xiaoying Decoction combined with levothyroxine sodium shows satisfactory efficacy in the treatment of Hashimoto’s hypothyroidism,which can obviously improve the clinical symptoms and thyroid function of patients,and reduce the levels of related antibodies.